1 Harvey K, Esposito DH, Han P, et al. Surveillance for travel-related disease – GeoSentinel Surveillance System, United States, 1997–2011. MMWR Surveill Summ. 2013;62:1–23.
2 White NJ, Dance DA, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet (London, England). 1989;2(8665):697–701.
3 Birnie E, Savelkoel J, Reubsaet F, et al. Melioidosis in travelers: An analysis of Dutch melioidosis registry data 1985-2018. Travel Med Infect Dis. 2019:101461.
4 Le Tohic S, Montana M, Koch L, Curti C, Vanelle P. A review of melioidosis cases imported into Europe. Eur J Clin Microbiol Infect Dis. 2019;38(8):1395–408.
5 Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med. 2012;367(11):1035–44.
6 Wiersinga WJ, Virk HS, Torres AG, et al. Melioidosis. Nat Rev Dis Primers. 2018;4:17107.
7 Chetchotisakd P, Chierakul W, Chaowagul W, et al. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet (London, England). 2014;383(9919):807–14.